STOCK WATCH

ANGLE is a company with an incredible piece of technology, but which seems to have flown undetected below the market’s radar.

It is the inventor and developer of parsortix, which picks up the tell-tale signs of cancer in the blood.

Yesterday, it was announced parsortix would be deployed in an independent trial in London that could potentially alter the way prostate cancer is treated.

Down 20pc so far this year, the shares were flat at 99p.